Molecular and structural consequences of early renal allograft injury  by Baboolal, Keshwar et al.
Kidney International, Vol. 61 (2002), pp. 686–696
Molecular and structural consequences of early renal
allograft injury
KESHWAR BABOOLAL, GERAINT A. JONES, ALENKA JANEZIC, DAVID R. GRIFFITHS, and
WIESLAW A. JUREWICZ
Welsh Transplant Research Group and Department of Pathology, University Hospital of Wales, Cardiff, Wales,
United Kingdom
3 months, 12% at 6 months and in 49% at 12 months. TheseMolecular and structural consequences of early renal allograft
changes in renal structure were not associated with any changeinjury.
in creatinine clearance (CCr): CCr 3 months, 56  2 mL/min,Background. Chronic allograft nephropathy is an important
CCr 24 months, 56  2 mL/min; P  NS. Stepwise regressioncause of graft failure. Many donor and recipient factors contrib-
analysis of key donor and recipient determinants of chronicute to its development. Prospective analysis of these factors has
renal injury identified calcineurin inhibitors and acute rejectionbeen hindered by the lack of sensitive and specific indicators of
episodes as important factors involved in the developmentrenal injury. As a consequence protocol biopsies have been
of chronic renal injury. In particular, the use of cyclosporineincreasingly used in the assessment of renal allograft injury.
compared to tacrolimus was associated with a tenfold increaseWe performed protocol renal allograft biopsies to prospectively
in TGF- mRNA (TGF- mRNA at 6 months, CsA vs. Tac,examine the role of important determinants and mediators of
chronic allograft nephropathy. 3  0.3 vs. 2  0.3 log copies, P  0.05), interstitial fibrosis
Methods. A total of 51 consecutive cadaveric renal transplant (Vvi at 6 months, CsA vs. Tac, 33  4% vs. 24  2%, P 
recipients entered a randomized prospective study of tacroli- 0.05). Changes in growth factors and renal structure predicted
mus (Tac) versus cyclosporine (CsA) microemulsion based impaired renal function (CCr at 12 months, CsA vs. Tac, 53 
immunosuppression. Study patients underwent protocol renal 4 mL/min vs. 62  2 mL/min, P  0.05). Similarly, acute rejec-
allograft biopsies at the time of engraftment and at 3, 6 and tion episodes were associated with an accelerated development
12 months post-transplantation. Biopsies were analyzed by of interstitial fibrosis (Vvi at 6 months, acute rejection vs. no
quantitative polymerase chain reaction (PCR) for mRNA for rejection, 34 3% vs. 25 2%; P 0.05), but not with changes
transforming growth factor- (TGF-), thrombospondin, and in TGF-, thrombospondin or fibronectin expression.
fibronectin. Measurements of renal structural injury were esti- Conclusion. Our results suggest that structural injury devel-
mated by quantitative assessment of interstitial fibrosis and ops early in the natural history of the renal allograft and is medi-
glomerulosclerosis. Changes in profibrotic growth factors and ated, in part, by the early up-regulation of profibrotic growth
renal structural injury were related to donor and recipient factors. We have determined that calcineurin inhibitors, in par-
determinants by stepwise regression analysis. ticular cyclosporine, and acute rejection episodes are key fac-
Results. Longitudinal assessment of renal injury demon- tors in the development of renal structural injury.
strated an early and progressive increase in mRNA for TGF-,
thrombospondin (TSP) and fibronectin (FBN): TGF- base-
line, 1.9 0.2 log copies; TGF- 6 months, 2.5 0.2 log copies,
Although there has been a significant improvement inP  0.05 6 months vs. baseline; TSP baseline, 1.9  0.2 log
copies; TSP 6 months, 2.4  0.2 log copies, P  0.05 6 months long-term graft survival during the last fifteen years, re-
vs. baseline; FBN baseline, 2.0 0.2 log copies; FBN 12 months, nal allografts continue to be lost at a rate of 2 to 4%
2.3  0.2 log copies, P  0.05 12 months vs. baseline. This per year after the first year of transplantation [1]. Long-
increase in profibrotic growth factors within the allograft was
term graft survival is determined principally by the devel-associated with a significant increase in interstitial fibrosis (Vvi)
opment of chronic renal allograft nephropathy [2, 3].on renal biopsies: Vvi baseline, 13  1%; Vvi 3 months, 18 
1%; Vvi 6 months, 28  2%; Vvi 12 months, 34  2%; P  Clinically, chronic renal allograft nephropathy is de-
0.05 3, 6, and 12 months vs. baseline. Histological analysis tected as a progressive and persistent decline in glomeru-
demonstrated chronic allograft nephropathy in 4% biopsies at lar filtration rate (GFR) in which histological analysis
reveals arteriolosclerosis, glomerulosclerosis and inter-
stitial fibrosis according to the Banff criteria [4]. Retro-Key words: TGF-, interstitial fibrosis, chronic allograft nephropathy,
fibrosis, kidney injury, cyclosporine. spective analyses of large patient databases have identi-
fied a number of key donor and recipient factors thatReceived for publication November 14, 2000
may influence the development of chronic allograft ne-and in revised form July 17, 2001
Accepted for publication September 14, 2001 phropathy and, therefore, long-term renal allograft sur-
vival [5–7]. 2002 by the International Society of Nephrology
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It is becoming increasingly clear that the response of (RT-PCR), to develop a sensitive and quantitative as-
sessment of renal fibrotic injury in protocol biopsies. Thethe renal allograft to injury, namely glomerulosclerosis
and interstitial fibrosis, is the same whatever the etiology rationale for this methodology was that the ability to
detect structural injury is enhanced if a quantitativeof the renal injury. Further, cross sectional studies of
renal tissue in patients with established chronic allograft rather than semiquantitative assessment of renal injury is
undertaken [20]. We hypothesized that this methodologynephropathy have suggested that the development of
glomerulosclerosis and interstitial fibrosis is mediated by would enable us to detect and identify key molecular
determinants of early renal allograft injury that wouldthe enhanced expression of the profibrotic growth factor,
transforming growth factor- (TGF-) [8–11]. Primary predate the onset of chronic allograft nephropathy.
regulation of TGF- activity is controlled by cleavage
of the latent TGF- precursor. Thrombospondin, a disul-
METHODS
fide linked trimer produced by connective tissue, is con-
Subjectssidered to be an important regulator of TGF- activity
in vivo [12]. A total of 51 consecutive cadaveric renal transplant
recipients performed between May 1997 and May 1998To determine the relative contributions of host and
donor factors in the development of chronic allograft consented to enter a randomized prospective study of ei-
ther tacrolimus (Prograf) or cyclosporine emulsion (Neo-nephropathy, and the potential for their modification
by therapeutic interventions, a prospective quantitative ral) based immunosuppression. Both groups received ste-
roids and azathioprine in addition to either tacrolimusevaluation of renal allograft injury is required. Unfor-
tunately, such studies have been limited by the lack of or cyclosporine. As part of the study, patients agreed to
a protocol renal allograft biopsies collected at the timesuitably sensitive assessments of early renal allograft
injury. of engraftment and at 3, 6 and 12 months post-trans-
plantation. A total of 202 biopsies were collected fromThis problem arises since renal injury is detected clini-
cally as a fall in creatinine clearance and the onset of all patients. The University Hospital of Wales Medical
Ethics Committee approved the study.proteinuria. However, a reduction in creatinine clear-
ance is a late sign of renal injury because compensatory Patients randomized to cyclosporine-based immuno-
suppression were dosed at approximately 8 mg/kg/daymechanisms within the kidney can maintain creatinine
clearance despite progressive structural injury [13]. The together with azathioprine at 1.5 mg/kg and a reducing
dose of prednisolone. Cyclosporine dosage was adjustedlack of sensitivity of creatinine clearance as a measure-
ment of renal injury is further exaggerated because se- to keep trough levels between 100 and 250 ng/mL. Pa-
tients randomized to tacrolimus based immunosuppres-rum creatinine is not an ideal filtration marker [14]. Simi-
larly, the finding of chronic allograft nephropathy on sion were dosed at approximately 0.2 mg/kg/day together
with azathioprine at 1.5 mg/kg and a reducing dose ofa renal biopsy is an indicator of poor long-term graft
outcome. The ability to detect chronic allograft nephrop- prednisolone. Tacrolimus dosage was adjusted to main-
tain trough levels between 5 and 15 ng/mL. A diagnosisathy is limited by the fact that biopsies are not usually
performed unless there has been a reduction in creati- of rejection was made in patients in whom there was a
greater than 10% increase in serum creatinine supportednine clearance. Further, the diagnosis of chronic allograft
nephropathy according to Banff criteria lacks the sensi- by a histological diagnosis of acute rejection according
to Banff criteria [21]. Prednisolone was withdrawn bytivity to detect renal injury as it relies on a semiquantita-
tive assessment of renal fibrosis. Therefore, there is a six months in patients who had not suffered from an
acute rejection episode.need to identify alternative methods to detect early renal
injury that can be used to describe key determinants of
Tissue harvestinglong-term graft function.
To overcome this problem, protocol renal biopsies Renal tissue was harvested at the time of engraftment
using a wedge biopsy and at 3, 6 and 12 months usinghave been increasingly utilized as a method of detecting
and identifying key determinants of renal injury. Several an automated biopsy gun (Manan, USA) fitted with an
18-gauge needle. Two samples were taken at each timegroups have used protocol biopsies to detect, follow the
course, and determine the molecular pathogenesis of point. Following the biopsy the specimens were in-
spected under light microscopy, to confirm adequacy ofsubclinical rejection [15–19].
The aim of this study was to utilize protocol biopsies sampling. Samples that failed to satisfy the Banff 1999
criteria for adequacy of sampling were discarded fromto identify key determinants and mediators of the re-
sponse of the renal allograft to injury, namely fibrosis, morphometric analysis [4]. One sample was then placed
in a CryoTube(r) (Nunc, Denmark) that was immedi-early in the natural history of the renal allograft. We
employed the methodologies of morphometry and quan- ately submersed in liquid nitrogen. The CryoTubes were
then transferred to a long-term storage vessel until thetitative reverse transcription-polymerase chain reaction
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time of processing for messenger RNA. The second bi-
opsy sample was fixed in formal saline prior to being
processed for histology and morphometric analysis.
RNA preparation
The renal tissue was crushed using disposable pestles,
in a sterile 1.5 mL microcentrifuge tube, while being kept
frozen by liquid nitrogen. The crushed material was fur-
ther macerated while immersed in TRIzol (Life Technol-
ogies, Paisley, UK) and total RNA extracted according
to the manufacturer’s instructions. Total RNA concen-
trations were determined by light absorbance at 260 nm
and the product purity determined by an A260/A280
absorbance ratio using a GeneQuant RNA/DNA calcu-
lator (Pharmacia Biotechnology, Uppsala, Sweden).
Reverse transcription
Total poly A mRNA from 500 ng of RNA from each
preparation was reverse transcribed (RT) in a 20 L re-
action at 42C for 45 minutes and 94C for three minutes
using poly (dT) 15 primers from the Promega RT-PCR
System (Promega, Madison, WI, USA). The RT-PCR
reaction was performed in a PE Applied Biosystems
GeneAmp PCR System 9700 thermal cycler (Valencia,
CA, USA). The RT products were diluted with 20 L
of water and subsequently 1 L of this was used per
10 L of PCR reaction.
Polymerase chain reaction
Rapid thermal cycling with continuous fluorometric
monitoring of the PCR products was performed in the
LightCycler (Idaho Technology, Idaho Falls, ID, USA).
This novel real-time PCR technique already has been
established as an efficient reproducible method for the
quantification of low and high copy numbers of mRNA
from various tissues [22–27].
Optimal magnesium (MgCl2) concentration and cy-
cling conditions are shown in Table 1. A 10 L PCR re-
action contained: 5 pmol of forward and reverse primer;
1 L of cDNA; 0.5 L 1:10000 dilution, sufficient to
achieve a fluorescent reading of between 3 and 5 on a
scale of 0 to 19 incorporated into the analysis software of
Sybr Green I (Bio/Gene Ltd, Kimbolton, Cambridge-
shire, UK), 2.5 L of H2O and 5 L of ready made 2
concentrated 2, 3 or 4 mmol/L Master Mix as indicated
in Table 1 (2 mmol/L, Cat #PCRM011; 3 mmol/L, Cat
#PCRM012; and 4 mmol/L, Cat #PCRM013; Bio/Gene).
Five microliters aliquots of the cDNA-PCR mix were
loaded into LightCycler capillary tubes. The thermal cy-
cling was carried out as ramping to 95C for one cycle,
followed by 45 cycles as outlined in Table 1. The temper-
ature transition rate was 20C per second for all primer
sets. Immediately after the extension phase of the last
PCR-cycle, the amplified PCR product was slowly heated
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from 72C to 97C at a rate of 0.3C/sec. The intensity of
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fluorescence in each sample was continuously monitored onto glass microscope slides (BDH Chemicals, Pool, Dor-
throughout the melting phase. The shape and position of set, UK). The sections were subsequently dewaxed and
temperature induced DNA-melting is the GC/AT ratio, stained with hematoxylin and eosin, and also the periodic
length and sequence dependent. DNA duplexes melted acid Schiff (PAS) reagent.
at characteristic temperatures that were indicated by the Biopsies were then assessed morphometrically by two
fluorescence quickly falling to background level. Analy- reviewers in order to determine a fibrosis index and
sis of the melting profile established a melting tempera- glomerulosclerosis score. The volume fraction of the
ture (Tm) for the amplified gene sequence. This was used cortical interstitium was determined by point counting
as an integral part of the system to verify the integrity of 100 m apart in each core [28]. The renal interstitial in-
the PCR product. jury was estimated by counting the relative interstitial
volume.
Ethidium bromide agarose gel electrophoresis An experienced renal histopathologist who was blinded
During optimization verification of the PCR product to the clinical origin of the biopsy performed Banff scor-
was performed by running the amplicon through a 2% ing according to the 1993 Banff criteria [21].
agarose gel in Tris-buffered eosin (TBE) buffer. Gels were
stained with ethidium bromide (0.5 g/mL), and photo- Renal function
graphed under ultraviolet (UV) illumination. Product Renal function was estimated using values of serum
size was verified by comparing it to a 100 base pair ladder creatinine. Glomerular filtration rate (GFR) was calcu-
(100 Base-Pair Ladder; Amersham-Pharmacia Biotech, lated in both donor and recipient from serum creatinine
Little Chalfont, UK). values using the Cockcroft-Gault formula [29].
Quantitative real-time PCR Statistical analysis
Cloning of the specific sequences of TGF-1, thrombo- Confirmation that each measured parameter approxi-
spondin-1 and fibronectin genes. Five microliters of each mated to a normal distribution as tested for by the Blom
of the non-purified TGF-1, thrombospondin 1 and fibro- method was obtained except for cytokine mRNA expres-
nectin PCR product was ligated into the pGEM (-T Vec- sion. In order to achieve normality for cytokine mRNA
tor System I; Promega) following the manufacturer’s expression, values were logarithmically transformed. For
instructions. E. coli competent cells were transformed comparisons of renal function, renal structure and cyto-
using a standard transformation protocol (JM109; Pro-
kine mRNA expression between each time point andmega). White colonies were grown overnight at 37C in
baseline, a paired t test was performed. To calculate theLB-Ampicillin medium. The WizardPlus SV Minipreps
correlation between cytokine expression as well as to doc-DNA Purification System was used to purify the cloned
ument the relationship between renal structure and func-gene. Template concentrations were determined by light
tion, a Pearson correlation was performed. These analy-absorbance at 260 nm and the product purity, determined
ses were further enhanced by the use of stepwise regres-by an A260/A280 absorbance ratio, gave values greater
sion where indicated. Analysis between observers forthan 1.8.
morphometric analysis was performed using the Altman-
Bland analysis [30]. Results are expressed as mean Cytokine mRNA quantification
SEM. P  0.05 was taken as being significant.The number of copies of the cloned gene sequence in
1 fg was calculated by combining the molecular weights
of the plasmid and the cloned sequence. The concentra- RESULTS
tions of the cloned gene sequences were adjusted to Clinical characteristics
provide 1010 copies per L of cDNA. Serial tenfold dilu-
The clinical characteristics of the 51 patients are showntions of the cloned gene were prepared and amplification
in Table 2. Twenty-four patients received cyclosporinereactions with these known initial copy numbers were
and 27 patients received tacrolimus. The two groups wererun in parallel with the amplification of unknown sam-
well matched for donor age, donor creatinine clearance,ples. At the end of the extension phase of each cycle,
HLA total mismatch and DR mismatch, and cold isch-the fluorescences of the unknown and the standard curve
emia time.samples were recorded. The data analysis program incor-
Acute rejection episodes (ARE) were significantly lowerporated into the system calculated the initial number of
in the tacrolimus treated patients compared to thosegene copies in the samples by extrapolating from the
patients treated with cyclosporine. Five patients (22%)standard curve.
in the tacrolimus group of patients developed acute rejec-
Histology and morphometry tion compared to eight patients (35%) in the cyclospo-
rine group. The average time of the ARE was in 35 The second biopsy collected was fixed in formal saline
and processed into wax. Serial sections were attached 13 days in the tacrolimus group of patients and 59  38
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Table 2. Donor and recipient cofactors in cyclosporine and tative PCR was performed on RNA isolated from pro-
tacrolimus treated patients
tocol biopsies performed at baseline, 3, 6 and 12 months
Cyclosporine Tacrolimus Significance following engraftment. The results of quantification of
(N24) (N27) P TGF-1, thrombospondin and fibronectin mRNA in pro-
Sex males/females 48:52 49:51 NS tocol renal biopsies are presented in Figure 1. These dem-
Donor age years 423 412 NS
onstrated an approximately tenfold increase in TGF-Donor CCr 966 997 NS
Delayed graft function 33% 27% NS and its main activator thrombospondin in renal allografts
DR mismatch 0.5 0.6 NS that preceded the expression of fibronectin. There was
Mismatch total 2.50.3 2.40.2 NS
a significant increase in renal allograft tissue expressionCold ischemia min 1165147 1220112 NS
3 month drug levels ng/mL 18123 101 of mRNA for TGF-1 at 6 and 12 months compared to
6 month drug levels ng/mL 14014 81 baseline. Thrombospondin mRNA increased over the
12 month drug levels ng/mL 13813 71
first six months compared to baseline.ARE 35% 22% 0.05
CMV disease 28% 25% NS Fibronectin mRNA increased progressively over the
first 12 months and reached statistical significance at 12Abbreviations are: CCr, creatinine clearance; ARE, acute rejection episodes;
CMV, cytomegalovirus. months compared to baseline. Activation of TGF- was
suggested by the strong correlation between TGF-1
mRNA expression and thrombospondin at 0, 3, 6 and
12 months (Fig. 2). The profibrotic effect of TGF- wasdays in the cyclosporine treated patients. The distribu-
further suggested by the strong correlation betweention of histological grades for acute rejection episodes
TGF-1 mRNA expression and fibronectin mRNA at 0,was similar in both groups, five patients developed Banff
6 and 12 months (Fig. 3).IV grade 1 rejection in the cyclosporine group and three
The intra-assay and interassay variation for repeatedin the tacrolimus group. Three patients in the cyclospo-
measurements of mRNA for each cytokine is demon-rine group and two in the tacrolimus group developed
strated in Table 3. These values are comparable to pub-Banff IV grade 2 rejection. Three pulses of methyl pred-
lished data using this technology and fall within generallynisolone 500 mg IV were given for each rejection epi-
accepted limits for quantitative RT-PCR.sode. If the acute rejection episode did not respond to
the steroid therapy, mycophenolate mofetil was substi-
Morphometric analysis of renal structuretuted for azathioprine; this occurred in four of eight
To determine whether enhanced expression of TGF-1,cyclosporine treated patients and one of the tacrolimus
thrombospondin and fibronectin mRNA signified en-treated patients. The higher incidence of rejection, to-
hanced renal fibrosis, morphometric analysis of protocolgether with the failure to respond to steroid therapy in
biopsies was performed. Structural renal injury was as-the cyclosporine treated patients with acute rejection,
sessed quantitatively by counting glomerulosclerosisresulted in a higher serum creatinine value at three
score and the relative volume of interstitial fibrosis onmonths compared to tacrolimus treated patients with
renal biopsies at 0, 3, 6 and 12 months. The averageacute rejection (cyclosporine 183  14 mol/L, tacroli-
number of glomerular profiles counted in each biopsymus 165 22mol/L; PNS). In addition, cyclosporine
was 20. Morphometric analysis of renal biopsy tissueand tacrolimus trough levels remained constant and
demonstrated a significant and progressive increase inwithin the accepted target levels at the time of protocol
interstitial fibrosis and glomerulosclerosis in protocol bi-biopsies.
opsies over the first 12 months (Table 4). Observer varia-Table 2 demonstrates that the incidence of delayed
tion for morphometric studies was 16%. Histologicalgraft function and cytomegalovirus (CMV) disease was
analysis revealed the presence of chronic allograft ne-similar in both cyclosporine and tacrolimus treated pa-
phropathy in 4% of biopsies at 3 months, 12% at 6tients. Standard antihypertensive therapies including cal-
months and in 49% at 12 months suggesting that quanti-cium antagonists, -blockers and -blockers were used
tative analysis of renal tissue provided a sensitive indica-in patients. Angiotensin-converting enzyme (ACE) in-
tor of renal injury. From Figure 1 and Table 4 it is alsohibitors or angiotensin II receptor antagonists were used
apparent that serial changes in cytokine expression andin 15% of patients on cyclosporine and 14% of patients
structural injury were not associated with a progressiveon tacrolimus. A target blood pressure (BP) of 140/
change in serum creatinine or glomerular filtration rate.80 mm Hg was achieved in 46% patients on cyclosporine
However, in agreement with other groups the extentand 48% patients on tacrolimus.
of interstitial fibrosis at 6 months correlated with renal
Quantification of renal TGF-1, thrombospondin and function at 24 months (Pearson correlation  0.557, P 
fibronectin mRNA 0.001), suggesting that structural injury is a sensitive indi-
cator of renal injury [31].To examine the synthesis of mRNA for TGF-, throm-
bospondin and fibronectin in the renal allograft quanti- To evaluate which factors contribute to the develop-
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Fig. 1. mRNA for transforming growth fac-
tor- (TGF-; ), thrombospondin 1 ( ), and
fibronectin () in renal allograft biopsies per-
formed at the time of engraftment (baseline)
and at 3, 6, and 12 months following en-
graftment. **P  0.05 at each time compared
to baseline.
Fig. 2. Regression analysis between TGF- mRNA expression and
thrombospondin 1 mRNA expression in renal allograft biopsies per- Fig. 3. Regression analysis between TGF- mRNA expression and
formed at baseline and at 3, 6, and 12 months following engraftment. fibronectin mRNA expression in renal allograft biopsies performed at
Symbols are: (solid line) baseline, N  45, Pearson coefficient  0.401, baseline and at 3, 6, and 12 months following engraftment. Symbols
P  0.005; (long dash) 3 months, N  47, Pearson coefficient  0.444, are: (solid line) baseline, N  47, Pearson coefficient  0.291, P 
P  0.002; (short hyphen) 6 months, N  48, Pearson coefficient  0.047; (long dashed line) 3 months, N  48, Pearson coefficient 0.273,
0.617, P  0.001; (heavy long dash short dash) 12 months, N  45, P  0.060; (short dashed line) 6 months, N  48, Pearson coefficient 
Pearson coefficient  0.432, P  0.002. 0.413, P  0.004; (dash dot dash) 12 months, N  50, Pearson coef-
ficient  0.392, P  0.005.
ment of interstitial fibrosis in protocol renal biopsies,
chronic allograft nephropathy in patients treated withregression analysis was performed for clinical variables
cyclosporine. Histological assessment of renal biopsiesthat have been associated with the development of
using Banff criteria, demonstrated that 55% of patientschronic allograft nephropathy. Enhanced tissue expres-
treated with cyclosporine had chronic allograft nephrop-sion of TGF- mRNA at 3, 6 and 12 months in-patients
athy at 12 months compared to 41% of patients treatedtreated with cyclosporine was comparable to those pa-
with tacrolimus. Differences in baseline renal histologytients treated with tacrolimus and this achieved statistical
could not account for subsequent differences in renalsignificance at 6 months (Fig. 4). In addition, TGF-
structure, as the glomerulosclerosis score and interstitialmRNA expression increased progressively in cyclospo-
fibrosis index were similar between the two groups (Ta-rine treated patients compared to tacrolimus treated pa-
ble 4). As might be expected, patients treated with cyclo-tients. Quantitative assessment of renal structural injury
sporine had worse renal function at 12 and 24 monthsdemonstrated that enhanced TGF- mRNA expression
(Fig. 6). Graft survival at 12 months and 24 monthswith cyclosporine was associated with increased intersti-
was similar between the two groups; graft survival withtial fibrosis in renal allograft biopsies at 3, 6 and 12
cyclosporine at 12 months 92% and at 24 months wasmonths following engraftment (Fig. 5). Increased inter-
stitial fibrosis corresponded to a higher incidence of 88%, while with tacrolimus at 12 months was 100% and
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Table 3. Interassay and intra-assay variation for repeated
measurements of mRNA for TGF-, thrombospondin
and fibronectin in renal allograft biopsies
Intra-assay Interassay
Assay Sample N variation variation
TGF-1 10e5 copies 8 0.05226 0.09699
10e3 copies 8 0.06818 0.17142
	ve control 8 0.06406 0.22171
Thrombospondin-1 10e6 copies 8 0.16611 0.03652
10e3 copies 8 0.10433 0.06385
	ve control 8 0.03412 0.10954
Fibronectin 10e6 copies 8 0.13879 0.03263
10e3 copies 8 0.12472 0.06931
	ve control 8 0.05567 0.02381
Fig. 4. TGF- expression in renal allograft biopsies in patients treated
with cyclosporine () or tacrolimus ( ). *P  0.05 tacrolimus vs.
cyclosporine; 
P  0.05 12 months, 6 months TGF- expression vs.
Table 4. Serial measurement of renal function and structure baseline.
in cadaveric renal allograft recipients
GS Vvi Vvt
Time CCr Creatinine
months mL/min lmol/L %
0 12 131 661
3 562 1475 51 181a 561
6 582 1444 133b 282b 512b
12 603 1486 155c 342c 422c
24 583 16311
Abbreviations are: CCr, creatinine clearance; GS, glomerulosclerosis; Vvi, rela-
tive volume of interstitial fibrosis; Vvt, fractional tubular volume.
a P  0.05 3 months vs. baseline
b P  0.05 6 months vs. baseline
c P  0.05 12 months vs. baseline
at 24 months was 96%. Table 2 shows that a lower rate
of acute rejection in patients treated with tacrolimus
existed compared to cyclosporine, but no difference was
Fig. 5. Interstitial fibrosis in renal allograft biopsies inpatients treatedfound in the distribution for other clinical variables.
with cyclosporine ( ) and tacrolimus ( ). **P  0.05 tacrolimus vs.Analysis of the effect of acute rejection episodes dem- cyclosporine; 
P 0.05 3, 6 and 12 months interstitial fibrosis vs. baseline
onstrated no significant relationship between acute re- in cyclosporine treated patients; P 0.05: 3, 6 and 12 months interstitial
fibrosis vs. baseline in tacrolimus treated patients.jection episodes and TGF-, thrombospondin and fi-
bronectin at any time point. However, there was a
relationship between acute rejection episodes and inter-
stitial fibrosis that reached statistical significance at 3, 6
and 12 months. Interstitial fibrosis in the acute rejection
group (N  13) versus no rejection group (N  38) at
baseline biopsy was 13  1 versus 13  1% (P  NS),
at the 3 month biopsy was 21  2% versus 17  1%
(P  0.05), at 6 month biopsy, 34  3% vs. 25  2%
(P  0.05), and at 12 month biopsy, 41  5% versus
31  2% (P  0.05). Renal function according to cre-
atinine clearance in the acute rejection group versus
no rejection group at 3 months was 46  3 versus 61 
3 mL/min (P  0.05), at 6 months, 50  4 versus 62 
3 mL/min (P  0.05), at 12 months, 50  5 versus
64  4 mL/min (P  0.05), and at 24 months was
51  6 versus 61  4 mL/min (P  NS). There was no
independent effect of donor age, CMV disease, sex, HLA Fig. 6. Creatinine clearance (CCr) in patients treated with cyclosporine
status, cold ischemia, delayed graft function on cytokine ( ) and tacrolimus ( ) at 3, 6, 12 and 24 months after engraftment.
*P  0.05 tacrolimus vs. cyclosporine.expression, renal structure or renal function.
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A stepwise regression analysis was performed to deter- stimulates proliferation of fibroblasts [33–35]. Throm-
bospondin is an extracellular matrix protein that acti-mine which of the two significant factors—drug regime
or acute rejection episodes—contributed most to the de- vates latent TGF- via a protease and cell independent
mechanism. Therefore, both TGF and thrombospondinvelopment of interstitial fibrosis in protocol biopsies and
to the deterioration in renal function. The effect of the mRNA were measured. Our study has demonstrated a
progressive and parallel increase in TGF- and throm-drug on interstitial fibrosis and renal function was found
to be significantly greater than acute rejection episodes. bospondin mRNA within the first six months of en-
graftment, suggesting up-regulation of active TGF-.Using this analysis it was possible to show that at 3, 6
and 12 months, 12%, 22% and 30%, respectively, of the TGF- subsequently acts in an autocrine or paracrine
fashion, where it enhances matrix synthesis and stimu-variation seen with interstitial fibrosis could be explained
by the drug alone. When acute rejection episodes were lates inhibitors of matrix degradation resulting in a net
increase in extracellular matrix, of which fibronectin isexamined in this model, acute rejection episodes ac-
counted for 7% of the variation in interstitial fibrosis at an important component. The up-regulation of fibronec-
tin in renal allograft tissue in our study suggests enhanced6 months and that this contribution remained stable at
7% at 12 months. The influence of the drug increased matrix synthesis. By inducing matrix synthesis and pre-
venting its degradation, measurements of TGF- to-with time following transplantation, but the influence of
acute rejection episodes remained constant. When the gether with thrombospondin and fibronectin can be con-
sidered to represent changes in matrix synthesis [36].analysis model involving drug and acute rejection epi-
sodes were examined further, it was noted that the contri- Although it is tempting to suggest that up-regulation
of TGF- mRNA together with thrombospondin and fi-butions made by both were of similar magnitude (at 6
and 12 months for interstitial fibrosis and 12 months for bronectin mRNA represent enhanced matrix synthesis,
the limitations of this methodology are recognized. It isrenal function) regardless of the order of entry into the
model. However, as expected, the analysis consistently likely that tissue levels of TGF- are modulated indepen-
dently of mRNA [37, 38]. In particular, the use of mRNAselected drug as the dominant factor in all time points
of TGF- and thrombospondin to represent active TGF-and for all determinant variables. This analysis suggests
together with the fact that measurements of matrix degra-that an orthogonal or additive relationship exists be-
dation were not made limits the strengths of the findings.tween the effect of drug regime and acute rejection epi-
Quantitative measurements of renal structure weresodes on interstitial fibrosis and renal function, with the
performed to directly measure the degree of interstitialcontribution of acute rejection achieving significance at
fibrosis and glomerulosclerosis. Our results support thethe time points indicated.
hypothesis of an enhanced matrix synthesis over degra-
dation, since progressive interstitial fibrosis and glomeru-
DISCUSSION losclerosis within renal allografts were found in the first
The aim of the current study was to develop a sensitive year. In agreement with recent studies the changes in
quantitative longitudinal assessment of renal allograft renal structure are preceded by increases in TGF- [39–
injury. We hypothesized that longitudinal measurements 40]. An interesting finding is the development of progres-
of renal allograft expression of TGF-, thrombospondin sive interstitial fibrosis despite a reduction in TGF- at
and fibronectin together with morphometric analysis of 12 months. One possible explanation is that, although
renal structure would provide a sensitive indicator of the rate of TGF- expression falls, the interstitial fibrosis
the response of the renal allograft to injury that would index represents the cumulative accumulation of fibrosis
predate the onset of chronic allograft nephropathy. We over the first year.
further hypothesized that this methodology would pro- Interestingly, the values for interstitial fibrosis and
vide a valuable insight into the early natural history of glomerulosclerosis within the first 6 months are less than
the renal allograft and would enable us to determine pros- those that one might expect in patients with established
pectively the influence of key determinants of chronic chronic allograft nephropathy [4]. Thus, it is not supris-
allograft nephropathy. ing, as our results demonstrate, that early structural in-
Our results have demonstrated early and sustained up- jury would not have been fully recognized using the
regulation of TGF-, thrombospondin and fibronectin semiquantitative criteria of the Banff schema. It is also
in renal allografts. TGF- was measured because it is apparent that it is difficult to use the Banff criteria to
considered to be an important mediator of interstitial fi- determine the relative contributions of clinical parame-
brosis in a diverse group of renal diseases including es- ters to the development of renal injury.
tablished chronic allograft nephropathy [32]. TGF- is When renal function was serially measured in this
secreted from resident and infiltrating cells in a non- group of patients it was noteworthy that serum creatinine
active form. Recent studies have demonstrated that remained remarkably stable within the first year. Indeed,
the average values of serum creatinine at 6 months sug-thrombospondin is a key activator of TGF- and also
Baboolal et al: Early renal allograft injury694
gested excellent allograft function, which would lead to At 3, 6 and 12 months, 12%, 22% and 30% of the varia-
tion seen with interstitial fibrosis could be explained byan expectation of good long-term graft survival [41].
However, since no formal estimate of GFR was made, the drug alone. In a majority of cases this increase in
interstitial fibrosis was due to cyclosporine. In particular,it is possible that differences in renal injury may have
been detected by a more sensitive assessment of GFR. there was a significant increase in TGF- and interstitial
fibrosis in-patients treated with cyclosporine comparedFurthermore, it is not possible to determine whether
the stability of serum creatinine reflected a stable GFR, to those treated with tacrolimus. These findings are con-
sistent with earlier work demonstrating enhanced TGF-compensatory changes within the kidney, or enhanced
tubular secretion of serum creatinine. The demonstra- expression in renal allografts treated with cyclosporine
[47–50]. This study also has shown that the rise in TGF-tion of progressive changes in renal structure within the
first year in our study does indicate that creatinine clear- and interstitial fibrosis predates the decline in function
in the cyclosporine treated patients. Our findings demon-ance was being maintained by compensatory hemody-
namic and structural changes within the renal allograft. strate that a quantitative assessment of growth factors
and renal structure provide a sensitive measure of allo-This hypothesis is supported by our and other groups’
studies showing that the early development of interstitial graft injury that allows key determinants of the renal
injury to be identified early in the natural history of thefibrosis in renal biopsies predated a progressive decline
in creatinine clearance [31, 42–46]. If this hypothesis is renal transplant.
A further finding has been that acute rejection epi-correct, it could explain why late acute rejection episodes
have such a significant effect on graft function and sur- sodes also are an important determinant of the develop-
ment of interstitial fibrosis. In our patients, acute rejec-vival. Our study suggests that there is little structural or
functional reserve within the allograft to compensate tion episodes accounted for 7% of the variation in
interstitial fibrosis at 6 and 12 months. We were unablefor additional insults. Interestingly, creatinine clearance
values at 3 and 6 months were lower in tacrolimus treated to demonstrate an effect of acute rejection episodes on
TGF- or other growth factors performed on protocolpatients than in cyclosporine treated patients, although
this did not reach statistical significance until 12 months. biopsies following the acute rejection episode. This find-
ing does not reject the hypothesis that TGF- is impor-This finding suggests that the two drugs have different
effects on renal hemodynamics. The lower GFR in cyclo- tant in the development of interstitial fibrosis following
acute rejection. It is possible that if TGF- or the othersporine treated patients might be explained by a greater
reduction in renal blood flow in the cyclosporine group growth factors had been measured at the time of the
acute rejection episode, then its up-regulation may havecompared to tacrolimus treated group.
Taken together, these findings demonstrate the early been demonstrated. However, it is possible that there is
an alternative pathway for the development of interstitialdevelopment of progressive and irreversible injury within
the renal allograft. These findings further suggest that fibrosis within the renal allograft during acute rejection
episodes. Additionally, the power of the study may notserial measurements of mediators of matrix synthesis
and morphometric analysis of renal structure provide a be sufficient to distinguish the effect of acute rejection
episodes on growth factors from those of the calcineurinsensitive indicator of renal injury that is apparent before
any change in renal function or the development of inhibitors. Our findings are consistent with those from
other studies demonstrating that both acute rejectionchronic allograft nephropathy according to Banff criteria.
The lack of sensitivity of serum creatinine and Banff episodes and cyclosporine nephrotoxicity are strong pre-
dictors for the subsequent development of chronic rejec-criteria for detecting early renal allograft injury has
handicapped investigators who have sought to identify tion [42, 51, 52].
Studies have demonstrated subclinical immune activ-key mediators of chronic allograft nephropathy. Conse-
quently, investigators have had to rely on large retrospec- ity and significant injury in protocol renal biopsies from
renal allografts with stable function [15–19]; the up-regu-tive analyses to identify key determinants. Although
these studies have the statistical power to identify impor- lation of key cytokines usually associated with acute re-
jection episodes and lymphocyte infiltration in protocoltant mediators, their ability to rank the importance of
each mediator’s role is limited. A prospective sensitive biopsies taken from patients with stable graft function
were identified. Those studies together with our presentanalysis of early renal injury has the potential to identify
and rank important mediators of renal injury. We there- findings suggest a persistent ongoing process of subclini-
cal immune and non-immune injury to the kidney re-fore examined whether the methodology employed in
this study, when followed longitudinally in protocol biop- sulting in progressive renal allograft fibrosis. Indeed, it is
possible that the failure to detect this subclinical immunesies, would provide a mechanism to assess potential me-
diators of early renal allograft injury. injury from 6 to 12 months, when the prednisolone was
withdrawn, may have contributed to the high incidenceOur study has demonstrated the important role of
calcineurin inhibitors in the development of renal injury. of chronic allograft nephropathy at the 12-month proto-
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